Ripple Therapeutics宣布与艾伯维公司达成合作和许可选择协议，共同开发下一代青光眼治疗方案
| 【新澳门内部资料精准大全】 |
| 【澳门今晚必中一肖一码准确9995】 |
| 【澳门一肖一码100准免费资料】 |
| 【2024年澳门正版资料大全公开】 |
| 【7777888888管家婆中特】 |
| 【澳门平特一肖100%免费】 |
| 【2024新澳彩料免费资料】 |
| 【新澳2024年精准一肖一码】 |
| 【2024年正版资料免费大全】 |
| 【管家婆一肖一码必中一肖】 |
| 【4949澳门免费资料大全特色】 |
| 【管家婆一肖-一码-一中一特】 |
| 【澳门今晚一肖码100准管家娶】 |
| 【2024澳门天天六开彩免费资料】 |
| 【管家婆一码一肖100中奖】 |
| 【澳门一码一肖一特一中直播开奖】 |
| 【2024澳门正版资料免费大全】 |
| 【澳门新葡萄新京6663】 |
| 【新澳门内部资料精准大全】 |
| 【2024澳门天天开好彩大全】 |
| 【4949澳门免费资料大全特色】 |
| 【澳门新葡萄新京8883游戏特色】 |
| 【澳门一码一肖一特一中2024】 |
| 【2024澳门特马今晚开奖】 |
| 【知乎:澳门王中王100%的资料】 |
| 【澳门天天开彩好正版挂牌】 |
- Collaboration to leverage AbbVie's eye care expertise and Ripple's innovative drug delivery platform to develop next-generation sustained release drug delivery implants for the treatment of glaucoma
TORONTO, ON / ACCESSWIRE / September 17, 2024 / Ripple Therapeutics today announced a collaboration and option-to-license agreement with AbbVie to develop RTC-620, a next generation, fully biodegradable, sustained release drug delivery intracameral implant with repeat dosing capabilities to reduce intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). This collaboration leverages AbbVie's expertise in eye care and Ripple's innovative drug delivery platform.
Ripple's patented technology platform is based on a discovery that drugs can be engineered into controlled release pharmaceuticals without the use of polymers or excipients. These proprietary prodrugs undergo surface erosion to give zero order release kinetics and are highly customizable to tailor both drug dose and duration. Because there are no polymers or excipients, once the drug is gone, the implant is gone with no pro-inflammatory degradation products, which supports repeat dosing.
"We're pleased to partner with AbbVie, a worldwide leader in ophthalmic therapeutics," said Tom Reeves, President and Chief Executive Officer, Ripple Therapeutics. "By combining our drug delivery platform with AbbVie's research, clinical, regulatory and commercial capabilities, we hope to deliver a meaningful impact on the lives of people living with glaucoma."
Millions of people are living with glaucoma, one of the leading causes of vision loss. New treatment options are needed to help patients challenged with topical drops or who are at risk for vision loss and looking for alternative treatment options.
"At AbbVie, we strive to find innovative solutions to build our portfolio of vision-preserving therapies," said Michael Robinson, M.D., Vice President and Therapeutic Area Head, Ophthalmology, AbbVie. "We are excited to partner with Ripple to further advance the development of RTC-620."
Under terms of the agreement, Ripple will lead preclinical development of RTC-620. Upon exercise of the option, AbbVie will lead the clinical and commercialization activities. Ripple will receive an upfront payment of $21.8 million from AbbVie and is eligible to receive up to $290 million in aggregate option fees and milestones, as well as tiered royalties on net sales.
About Ripple Therapeutics
Ripple Therapeutics Corporation is a privately held clinical stage company focused on improving ophthalmic therapeutics with controllable sustained delivery implants without the use of polymers or excipients. Our novel therapeutics provide better outcomes for patients, easier management of care for physicians and lower cost for payors.
Piper Sandler acted as the exclusive financial advisor to Ripple.
For further information:
Media: Julie Fotheringham, [email protected], 416-951-7988
SOURCE: Ripple Therapeutics
本文由浅萤唤森于2024-09-17发表在qygqdj，如有疑问，请联系我们。
本文链接：https://dsfkyy.com/post/197789.html
发表评论